Health Care [ 4/12 ] | Health Care Equipment & Supplies [ 43/72 ]
NASDAQ | Common Stock
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
It operates in two segments: Global Logistics Solutions and Global Bioservices.
The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.
It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing.
In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; and MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C.
Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services.
Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 24 | -0.43 Decreased by -168.75% | -0.35 Decreased by -22.86% |
| Mar 12, 24 | -1.31 Decreased by -445.83% | -0.29 Decreased by -351.72% |
| Nov 8, 23 | -0.31 Decreased by -106.67% | -0.30 Decreased by -3.33% |
| Aug 9, 23 | -0.42 Decreased by -82.61% | -0.24 Decreased by -75.00% |
| May 4, 23 | -0.16 Increased by +48.39% | -0.19 Increased by +15.79% |
| Feb 23, 23 | -0.24 Decreased by -118.18% | -0.19 Decreased by -26.32% |
| Nov 3, 22 | -0.15 Increased by +16.67% | -0.14 Decreased by -7.14% |
| Aug 4, 22 | -0.23 Decreased by -43.75% | -0.15 Decreased by -53.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 56.16 M Decreased by -7.12% | -13.27 M Decreased by -149.60% | Decreased by -23.63% Decreased by -168.75% |
| Jun 30, 23 | 57.02 M Decreased by -11.12% | -18.36 M Decreased by -100.01% | Decreased by -32.19% Decreased by -125.03% |
| Mar 31, 23 | 62.82 M Increased by +20.10% | -5.57 M Increased by +58.42% | Decreased by -8.87% Increased by +65.38% |
| Dec 31, 22 | 60.36 M Increased by +6.94% | -9.44 M Increased by +96.37% | Decreased by -15.63% Increased by +96.61% |
| Sep 30, 22 | 60.46 M Increased by +6.65% | -5.32 M Increased by +18.54% | Decreased by -8.79% Increased by +23.62% |
| Jun 30, 22 | 64.15 M Increased by +14.17% | -9.18 M Decreased by -70.29% | Decreased by -14.30% Decreased by -49.16% |
| Mar 31, 22 | 52.30 M Decreased by -1.84% | -13.40 M Decreased by -280.04% | Decreased by -25.63% Decreased by -287.18% |
| Dec 31, 21 | 56.44 M Increased by +16.71% | -260.09 M Decreased by -2.16 K% | Decreased by -460.82% Decreased by -1.83 K% |